HEMAB THERAPEUTICS HOLDINGS (COAG) Stock Price, News & Analysis
Company Description
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company developing therapies for blood coagulation disorders. The company focuses on treatments intended to address rare bleeding conditions, including Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its common stock trades on the Nasdaq Global Select Market under the symbol COAG.
The company's lead program is sutacimig (HMB-001), a bispecific antibody being developed as a prophylactic therapy for Glanzmann thrombasthenia and Factor VII deficiency. Hemab's work is centered on coagulation biology and the development of therapeutic candidates for patients with inherited or rare bleeding disorders.
Hemab reports one operating segment focused on the research and development of prophylactic therapeutics for bleeding disorders. As a clinical-stage biotechnology issuer, its operating model is based on advancing drug candidates through research, development, and regulatory processes before any potential commercialization.
Stock Performance
HEMAB THERAPEUTICS HOLDINGS (COAG) stock last traded at $31.49, up 8.46% from the previous close. Over the past 12 months, the stock has lost 0.3%. At a market capitalization of $1.4B, COAG is classified as a small-cap stock with approximately 46.7M shares outstanding.
COAG Rankings
Latest News
HEMAB THERAPEUTICS HOLDINGS has 5 recent news articles. Of the recent coverage, 2 articles coincided with positive price movement and 2 with negative movement. Key topics include earnings, IPO, offering. View all COAG news →
SEC Filings
HEMAB THERAPEUTICS HOLDINGS has filed 5 recent SEC filings, including 3 Form 4, 1 Form 10-Q, 1 Form 8-K. The most recent filing was submitted on June 17, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all COAG SEC filings →
Insider Radar
Insider buying activity at HEMAB THERAPEUTICS HOLDINGS over the past 90 days may reflect management confidence in the company's direction. Institutional investors and analysts often monitor insider purchases as a potential bullish indicator for the stock.
Financial Highlights
Upcoming Events
ISTH 2026 presentations
HEMAB THERAPEUTICS HOLDINGS has 1 upcoming scheduled event. The next event, "ISTH 2026 presentations", is scheduled for July 11, 2026 (tomorrow). Investors can track these dates to stay informed about potential catalysts that may affect the COAG stock price.
Short Interest History
Short interest in HEMAB THERAPEUTICS HOLDINGS (COAG) currently stands at 1.4 million shares, up 32.0% from the previous reporting period, representing 3.3% of the float. Over the past 12 months, short interest has increased by 78.6%. This relatively low short interest suggests limited bearish sentiment. The 7.5 days to cover indicates moderate liquidity for short covering.
Days to Cover History
Days to cover for HEMAB THERAPEUTICS HOLDINGS (COAG) currently stands at 7.5 days, up 16.3% from the previous period. This moderate days-to-cover ratio suggests reasonable liquidity for short covering, requiring about a week of average trading volume. The days to cover has increased 518.9% over the past year, indicating either rising short interest or declining trading volume. The ratio has shown significant volatility over the period, ranging from 1.2 to 7.5 days.
COAG Company Profile & Sector Positioning
HEMAB THERAPEUTICS HOLDINGS (COAG) operates in the Biotechnology industry within the broader Biological Products, (no Diagnostic Substances) sector and is listed on the NASDAQ. In monthly performance, the stock ranks #3,302 among all tracked companies.